In an interview at the DIA Global Annual Meeting with Nicholas Saraceno, Cal Collins, CEO of OpenClinica discusses his passion for SMART on FHIR.
Phase III KEYNOTE-564 Trial Data Show Keytruda Improves Survival in Renal Cell Carcinoma
January 29th 2024Trial shows Keytruda improved overall survival by 38% compared with placebo in in patients with renal cell carcinoma at intermediate-high or high risk of recurrence after nephrectomy or nephrectomy and resection of metastatic lesions.